Generics giant Teva sees drug sales erosion on loss of exclusivity

9 May 2016
drugs_pills_tablets_big

Israel-based generics giant Teva Pharmaceutical Industries (NYSE: TEVA) posted first-quarter 2016 financials, indicating that it is itself facing competition for its branded copy medicines.

However, the results beat analysts’ expectations and the firm’s share rose 3% to $51.76 in pre-market trading.

On an adjusted basis, Teva's net earnings fell 5.1% to $1.11 billion, while earnings per share fell 11.8% to $1.20. That was $0.03 a share higher than the Wall Street analysts' expectations.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics